Myostatin (MSTN) is a well-reported negative regulator of muscle growth and a member of
the transforming growth factor (TGF) family. MSTN has important functions in skeletal muscle …

Myostatin (GDF-8) was discovered 25 years ago as a new transforming growth factor-β
family member that acts as a master regulator of skeletal muscle mass. Myostatin is made by …

Osteosarcopenia is a burgeoning geriatric syndrome and a familiar disease among older
individuals. It is characterized by reduced skeletal muscle mass and bone mineral density …

Background Bone metabolism has been proposed to be affected by the activins-follistatins-
inhibins (AFI) hormonal system. We aimed to evaluate AFI in patients with osteoporosis and …

Clinical studies revealed a relationship between osteoporosis and sarcopenia. Based on
this background, crosstalk between muscle and bone has emerged as a novel research field …

Background Myostatin (MSTN) is a transforming growth factor-ß superfamily member that
acts as a major regulator of skeletal muscle mass. GDF-11, which is highly related to MSTN …

BP has shown good potential for promoting bone regeneration. However, the understanding
of the mechanisms of BP-enhanced bone regeneration is still limited. This review first …

The activins–follistatins–inhibins (AFI) hormonal system affects bone metabolism.
Treatments that alter bone metabolism may also alter the AFI molecules. In this non …

Myostatin, a member of the transforming growth factor‐β superfamily, is a pivotal regulator of
skeletal muscle growth in mammals. Its discovery has sparked significant interest due to its …

Follistatin is a member of the activin–follistatin–inhibin hormonal system and is proposed to
affect bone metabolism. However, data regarding the effect of follistatin on bone are …